Non-arteritic anterior ischemic optic neuropathy (NA-AION) represents one of the most important causes of blindness or severely impaired vision in middle-aged and elderly people. Unilateral optic disc edema and abrupt, painless vision loss are its defining features. It is commonly assumed that NA-AION is caused by an ischemic infarction of the optic nerve head, and, although the exact pathogenesis is still unknown, several risk factors and comorbidities associated with its development have been found. NA-AION occurs generally in patients older than 50 years who have small optic discs and vasculopathy risk factors. Even though numerous treatment options have been proposed, no available effective medical or surgical therapy or prophylactic measure for NA-AION currently exists. The purpose of present-day therapeutic strategies is therefore to identify and possibly control any underlying modifiable risk factors, aiming to prevent the development of new NA-AION episodes in the affected and fellow eye. A thorough assessment of NAION, including its history, epidemiology, etiology, pathophysiology, risk factors, associated comorbidities, clinical findings, diagnostic tests, treatment choices, prognosis, and future research, is the goal of this work.

Non-arteritic anterior ischemic optic neuropathy (NA-AION): a comprehensive overview / Salvetat, Maria Letizia; Pellegrini, Francesco; Spadea, Leopoldo; Salati, Carlo; Zeppieri, Marco. - In: VISION. - ISSN 2411-5150. - 7:4(2023). [10.3390/vision7040072]

Non-arteritic anterior ischemic optic neuropathy (NA-AION): a comprehensive overview

Spadea, Leopoldo
Supervision
;
2023

Abstract

Non-arteritic anterior ischemic optic neuropathy (NA-AION) represents one of the most important causes of blindness or severely impaired vision in middle-aged and elderly people. Unilateral optic disc edema and abrupt, painless vision loss are its defining features. It is commonly assumed that NA-AION is caused by an ischemic infarction of the optic nerve head, and, although the exact pathogenesis is still unknown, several risk factors and comorbidities associated with its development have been found. NA-AION occurs generally in patients older than 50 years who have small optic discs and vasculopathy risk factors. Even though numerous treatment options have been proposed, no available effective medical or surgical therapy or prophylactic measure for NA-AION currently exists. The purpose of present-day therapeutic strategies is therefore to identify and possibly control any underlying modifiable risk factors, aiming to prevent the development of new NA-AION episodes in the affected and fellow eye. A thorough assessment of NAION, including its history, epidemiology, etiology, pathophysiology, risk factors, associated comorbidities, clinical findings, diagnostic tests, treatment choices, prognosis, and future research, is the goal of this work.
2023
NA-AION pathophysiology; NA-AION risk factors; NA-AION treatment options; ischemic optic neuropathy (ION); non-arteritic anterior ischemic optic neuropathy (NA-AION)
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Non-arteritic anterior ischemic optic neuropathy (NA-AION): a comprehensive overview / Salvetat, Maria Letizia; Pellegrini, Francesco; Spadea, Leopoldo; Salati, Carlo; Zeppieri, Marco. - In: VISION. - ISSN 2411-5150. - 7:4(2023). [10.3390/vision7040072]
File allegati a questo prodotto
File Dimensione Formato  
Salvetat_Non-Arteritic Anterior_2023.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 517.19 kB
Formato Adobe PDF
517.19 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1693265
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 12
social impact